Relmada Therapeutics, Inc.(RLMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RLMD Relmada Therapeutics, Inc.

Market Closed 12-12 16:00:00 EST

4.06

-0.13

-3.10%

盘后4.04

-0.02-0.49%

17:56 EST

High4.59	Low4.01	Vol1.62M
Open4.22	D1 Closing4.19	Amplitude13.72%
Mkt Cap297.73M	Tradable Cap256.39M	Total Shares73.33M
T/O7.02M	T/O Rate2.57%	Tradable Shares63.15M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RLMD","market":"US","secType":"STK","nameCN":"Relmada Therapeutics, Inc.","latestPrice":4.06,"timestamp":1765573200000,"preClose":4.19,"halted":0,"volume":1621941,"hourTrading":{"tag":"盘后","latestPrice":4.04,"preClose":4.06,"latestTime":"17:56 EST","volume":56311,"amount":228641.3063,"timestamp":1765580176898},"delay":0,"floatShares":63149200,"shares":73333622,"eps":-1.769318,"marketStatus":"Market Closed","change":-0.13,"latestTime":"12-12 16:00:00 EST","open":4.22,"high":4.585,"low":4.01,"amount":7019762.269941,"amplitude":0.137232,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.769318,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":4.19,"preHourTrading":{"tag":"盘前","latestPrice":4.23,"preClose":4.19,"latestTime":"09:11 EST","volume":128,"amount":543.3300224,"timestamp":1765548693824},"postHourTrading":{"tag":"盘后","latestPrice":4.04,"preClose":4.06,"latestTime":"17:56 EST","volume":56311,"amount":228641.3063,"timestamp":1765580176898},"volumeRatio":1.5819644419841556,"impliedVol":2.2951,"impliedVolPercentile":0.82},"requestUrl":"/m/hq/s/RLMD/wiki","defaultTab":"wiki","newsList":[{"id":"2584791427","title":"Mizuho Securities upgrades Relmada Therapeutics (RLMD) to a Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2584791427","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584791427?lang=en_us&edition=fundamental","pubTime":"2025-11-19 17:35","pubTimestamp":1763544910,"startTime":"0","endTime":"0","summary":"Mizuho Securities analyst Uy Ear upgraded Relmada Therapeutics to a Buy today and set a price target of $10.00. Ear covers the Healthcare sector, f...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mizuho-securities-upgrades-relmada-therapeutics-rlmd-to-a-buy-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mizuho-securities-upgrades-relmada-therapeutics-rlmd-to-a-buy-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RLMD","MFG"],"gpt_icon":0},{"id":"2584363911","title":"Relmada Therapeutics Inc : Mizuho Raises to Outperform From Neutral; Raises Target Price to $10 From $1","url":"https://stock-news.laohu8.com/highlight/detail?id=2584363911","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584363911?lang=en_us&edition=fundamental","pubTime":"2025-11-19 17:04","pubTimestamp":1763543065,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nFWN3WV0G1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RLMD","BK4007"],"gpt_icon":0},{"id":"2581060576","title":"Relmada Therapeutics CAO and COO Chuck Ence Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2581060576","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581060576?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:31","pubTimestamp":1762432271,"startTime":"0","endTime":"0","summary":"Chuck Ence, Chief Accounting Officer and Chief Operating Officer of Relmada Therapeutics Inc., has reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relmada Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 06, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL5wyNMk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLMD","BK4007"],"gpt_icon":0},{"id":"2581603090","title":"Relmada Therapeutics CFO Maged Shenouda Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2581603090","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581603090?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:30","pubTimestamp":1762432244,"startTime":"0","endTime":"0","summary":"Maged Shenouda, Chief Financial Officer of Relmada Therapeutics Inc., has reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relmada Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 06, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL5xW1ld:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Relmada Therapeutics CFO Maged Shenouda Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RLMD"],"gpt_icon":0},{"id":"2580731722","title":"Relmada Therapeutics announces FDA feedback on study paths for NDV-01","url":"https://stock-news.laohu8.com/highlight/detail?id=2580731722","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580731722?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:50","pubTimestamp":1762260653,"startTime":"0","endTime":"0","summary":"Relmada Therapeutics (RLMD) announced the receipt of written minutes from a Type B pre-IND meeting with the U.S. Food and Drug Administration, FDA,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/relmada-therapeutics-announces-fda-feedback-on-study-paths-for-ndv-01-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/relmada-therapeutics-announces-fda-feedback-on-study-paths-for-ndv-01-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","BK4539","RLMD","LENZ"],"gpt_icon":0},{"id":"2580731248","title":"Relmada Therapeutics prices 40.1M shares at $2.20 in underwritten offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2580731248","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580731248?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:50","pubTimestamp":1762260630,"startTime":"0","endTime":"0","summary":"Relmada Therapeutics (RLMD) announced the pricing of its underwritten offering of 40,142,000 shares of its common stock and, in lieu of common stoc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/relmada-therapeutics-prices-40-1m-shares-at-2-20-in-underwritten-offering-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/relmada-therapeutics-prices-40-1m-shares-at-2-20-in-underwritten-offering-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RLMD","BK4139","LENZ","BK4539","BK4007"],"gpt_icon":0},{"id":"2580739041","title":"BRIEF-Relmada Gets FDA Support For Two Registrational Study Paths For NDV-01 In Non-Muscle Invasive Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2580739041","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580739041?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:46","pubTimestamp":1762260390,"startTime":"0","endTime":"0","summary":"BRIEF-Relmada Gets FDA Support For Two Registrational Study Paths For NDV-01 In Non-Muscle Invasive Bladder CancerNov 4 (Reuters) - Relmada Therapeutics Inc RLMD.O:RELMADA ANNOUNCES FDA FEEDBACK SUPPO","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nTUA8NSXQG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLMD","BK4007"],"gpt_icon":0},{"id":"2580373523","title":"Relmada Therapeutics Inc: Common Stock Are Being Sold at an Offering Price of $2.20 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2580373523","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580373523?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:09","pubTimestamp":1762258193,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nTUA19PPGB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RLMD","BK4007"],"gpt_icon":0},{"id":"2580773301","title":"Relmada Therapeutics Inc - Secures FDA Alignment for Phase 3 Ndv-01 Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2580773301","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580773301?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:01","pubTimestamp":1762257660,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nTUA8NSXQG:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RLMD","BK4007"],"gpt_icon":0},{"id":"2580733033","title":"Relmada Therapeutics Inc - FDA Confirms No Additional Non-Clinical Studies Required for Ndv-01","url":"https://stock-news.laohu8.com/highlight/detail?id=2580733033","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580733033?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:01","pubTimestamp":1762257660,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nTUA8NSXQG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","RLMD"],"gpt_icon":0},{"id":"2580733032","title":"Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for Ndv-01 in Non-Muscle Invasive Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2580733032","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580733032?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:01","pubTimestamp":1762257660,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nTUA8NSXQG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","RLMD"],"gpt_icon":0},{"id":"2580330307","title":"Relmada Therapeutics Inc: Initiating Phase 3 Programs in First Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2580330307","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580330307?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:01","pubTimestamp":1762257660,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nTUA8NSXQG:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RLMD","BK4007"],"gpt_icon":0},{"id":"2573595250","title":"BRIEF-Relmada Therapeutics Appoints Max Kates, MD, To The Clinical Advisory Board To Support Development Of NDV-01","url":"https://stock-news.laohu8.com/highlight/detail?id=2573595250","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573595250?lang=en_us&edition=fundamental","pubTime":"2025-10-07 19:52","pubTimestamp":1759837944,"startTime":"0","endTime":"0","summary":"BRIEF-Relmada Therapeutics Appoints Max Kates, MD, To The Clinical Advisory Board To Support Development Of NDV-01Oct 7 (Reuters) - Relmada Therapeutics Inc RLMD.O:RELMADA THERAPEUTICS APPOINTS DISTIN","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nTUA3NBVM4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RLMD"],"gpt_icon":0},{"id":"2567100439","title":"Relmada Regains Compliance With Nasdaq Minimum Bid Price Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2567100439","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567100439?lang=en_us&edition=fundamental","pubTime":"2025-09-16 21:00","pubTimestamp":1758027600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250916:nTUA2K13SG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","RLMD"],"gpt_icon":0},{"id":"2567027131","title":"Relmada Therapeutics Inc - Regains Compliance With Nasdaq Minimum Bid Price - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2567027131","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567027131?lang=en_us&edition=fundamental","pubTime":"2025-09-16 20:12","pubTimestamp":1758024768,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250916:nFWN3V302I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","RLMD"],"gpt_icon":0},{"id":"2566609112","title":"Relmada Therapeutics Inc. Publishes Mid-Year 2025 Shareholder Letter","url":"https://stock-news.laohu8.com/highlight/detail?id=2566609112","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566609112?lang=en_us&edition=fundamental","pubTime":"2025-09-10 20:46","pubTimestamp":1757508408,"startTime":"0","endTime":"0","summary":"Relmada Therapeutics Inc. issued a mid-year letter to shareholders, signed by Chief Executive Officer Sergio Traversa. The letter provides an update on the company's progress and outlines recent strategic developments. A comprehensive strategic review led to the addition of two Phase 2 product candidates: NDV-01, for non-muscle invasive bladder cancer, and Sepranolone, for compulsivity disorders such as Prader-Willi Syndrome. Six-month follow-up data from the Phase 2 study of NDV-01 showed a 91% complete response rate. Preparations are underway to initiate a Phase 3 trial in the first half of 2026. The letter also discusses upcoming activities related to Sepranolone, including FDA engagement and manufacturing activities planned for the second half of 2025, and the initiation of a Phase 2 study in the first half of 2026. The full letter can be accessed through the link below.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nNDL5xGxnF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RLMD"],"gpt_icon":0},{"id":"2564801513","title":"Relmada Therapeutics Inc. Announces Availability of Regulation FD Disclosure","url":"https://stock-news.laohu8.com/highlight/detail?id=2564801513","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564801513?lang=en_us&edition=fundamental","pubTime":"2025-09-02 19:31","pubTimestamp":1756812705,"startTime":"0","endTime":"0","summary":"Relmada Therapeutics Inc. announced that Raj S. Pruthi, MD, Chief Medical Officer-Urology, purchased 55,000 shares of the company's common stock in open market transactions on August 29, 2025. This transaction was disclosed in a Form 8-K filed under Regulation FD Disclosure. The document does not include a URL where it has been posted.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relmada Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 02, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nNDLcck450:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RLMD"],"gpt_icon":0},{"id":"2563801061","title":"Sergio Traversa, CEO of Relmada Therapeutics Inc., Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2563801061","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563801061?lang=en_us&edition=fundamental","pubTime":"2025-08-29 04:57","pubTimestamp":1756414630,"startTime":"0","endTime":"0","summary":"Sergio Traversa, Chief Executive Officer of Relmada Therapeutics Inc., reported an acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relmada Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 28, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250828:nNDL6hgDv8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLMD","BK4007"],"gpt_icon":0},{"id":"2557599382","title":"Relmada Therapeutics Q2 EPS $-0.3","url":"https://stock-news.laohu8.com/highlight/detail?id=2557599382","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557599382?lang=en_us&edition=fundamental","pubTime":"2025-08-08 04:25","pubTimestamp":1754598311,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nPLXC1CB60:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","RLMD"],"gpt_icon":0},{"id":"2557596872","title":"Relmada Therapeutics Inc - Phase 2 Study for Sepranolone in Prader-Willi Syndrome in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2557596872","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557596872?lang=en_us&edition=fundamental","pubTime":"2025-08-08 04:05","pubTimestamp":1754597108,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nTUA327B0Q:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","RLMD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.relmada.com","stockEarnings":[{"period":"1week","weight":-0.0425},{"period":"1month","weight":0.0384},{"period":"3month","weight":1.5535},{"period":"6month","weight":4.7983},{"period":"1year","weight":9.973},{"period":"ytd","weight":6.8077}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":-0.006257},{"month":2,"riseRate":0.571429,"avgChangeRate":0.05562},{"month":3,"riseRate":0.571429,"avgChangeRate":-0.024636},{"month":4,"riseRate":0.714286,"avgChangeRate":0.052877},{"month":5,"riseRate":0.5,"avgChangeRate":0.173917},{"month":6,"riseRate":0.125,"avgChangeRate":-0.123736},{"month":7,"riseRate":0.75,"avgChangeRate":0.083628},{"month":8,"riseRate":0.5,"avgChangeRate":0.100482},{"month":9,"riseRate":0.875,"avgChangeRate":0.190291},{"month":10,"riseRate":0.5,"avgChangeRate":0.106137},{"month":11,"riseRate":0.375,"avgChangeRate":0.05543},{"month":12,"riseRate":0.375,"avgChangeRate":-0.01674}],"exchange":"NASDAQ","name":"Relmada Therapeutics, Inc.","nameEN":"Relmada Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Relmada Therapeutics, Inc.(RLMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Relmada Therapeutics, Inc.(RLMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Relmada Therapeutics, Inc.,RLMD,Relmada Therapeutics, Inc.股票,Relmada Therapeutics, Inc.股票老虎,Relmada Therapeutics, Inc.股票老虎国际,Relmada Therapeutics, Inc.行情,Relmada Therapeutics, Inc.股票行情,Relmada Therapeutics, Inc.股价,Relmada Therapeutics, Inc.股市,Relmada Therapeutics, Inc.股票价格,Relmada Therapeutics, Inc.股票交易,Relmada Therapeutics, Inc.股票购买,Relmada Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Relmada Therapeutics, Inc.(RLMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Relmada Therapeutics, Inc.(RLMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction